IASLC WCLC 2021: Nivolumab and Ipilimumab Plus Chemotherapy Beneficial for Advanced Non–Small Cell Lung Cancer With or Without Brain Metastases
Findings support benefit of this combination for first-line therapy in advanced disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.